{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T13:02:11Z","timestamp":1770037331215,"version":"3.49.0"},"reference-count":189,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jinf.2017.03.005","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T20:16:07Z","timestamp":1489695367000},"page":"527-544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pneumolysin as a potential therapeutic target in severe pneumococcal disease"],"prefix":"10.1016","volume":"74","author":[{"given":"Ronald","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2017.03.005_bib1","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.1016\/j.ijid.2010.02.2262","article-title":"Clinical and economic burden of pneumonia among adults in Latin America","volume":"14","author":"Isturiz","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3810\/pgm.2010.03.2130","article-title":"Burden of community-acquired pneumonia in North American adults","volume":"122","author":"File","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib3","first-page":"108","article-title":"Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region","volume":"38","author":"Song","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2017.03.005_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.jinf.2017.03.005_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1055\/s-0032-1315634","article-title":"Microbiology and risk factors for community-acquired pneumonia","volume":"33","author":"Sanz Herrero","year":"2012","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/1469-0691.12461","article-title":"Pneumococcal infection in adults: burden of disease","volume":"20","author":"Drijkoningen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2017.03.005_bib7","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.vaccine.2006.09.008","article-title":"The preventable burden of pneumococcal disease in the developing world","volume":"25","author":"Scott","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2017.03.005_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1183\/09059180.00008911","article-title":"The remaining challenges of pneumococcal disease in adults","volume":"21","author":"Ludwig","year":"2012","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jinf.2017.03.005_bib9","doi-asserted-by":"crossref","first-page":"e60273","DOI":"10.1371\/journal.pone.0060273","article-title":"Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques","volume":"8","author":"Said","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jinf.2017.03.005_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12890-016-0242-0","article-title":"A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults","volume":"16","author":"Chalmers","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib11","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","article-title":"Risk factors for community-acquired pneumonia in adults in Europe: a literature review","volume":"68","author":"Torres","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jinf.2017.03.005_bib12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrmicro3231","article-title":"The co-pathogenesis of influenza viruses with bacteria in the lung","volume":"12","author":"McCullers","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jinf.2017.03.005_bib13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","article-title":"Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease","volume":"70","author":"Torres","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.jinf.2017.03.005_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijid.2015.05.003","article-title":"Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence","volume":"37","author":"Curcio","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib15","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.12688\/f1000research.9283.1","article-title":"Epidemiology, virulence factors and management of the pneumococcus","volume":"5","author":"Feldman","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.jinf.2017.03.005_bib16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/CMR.00048-09","article-title":"Infections of people with complement deficiencies and patients who have undergone splenectomy","volume":"23","author":"Ram","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jinf.2017.03.005_bib17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.medmal.2012.04.003","article-title":"Pneumococcal infections and adult with risk factors","volume":"42","author":"Chidiac","year":"2012","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.jinf.2017.03.005_bib18","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.ijsu.2014.11.005","article-title":"Overwhelming post splenectomy infection syndrome \u2013 review study","volume":"12","author":"Sinwar","year":"2014","journal-title":"Int J Surg"},{"key":"10.1016\/j.jinf.2017.03.005_bib19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/cid\/civ1195","article-title":"Overwhelming postsplenectomy infection: a prospective multicenter cohort study","volume":"62","author":"Theilacker","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijid.2013.10.020","article-title":"Immunoglobulin deficiency in patients with Streptococcus pneumoniae or Haemophilus influenzae invasive infections","volume":"79","author":"Martinot","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1128\/CMR.00001-11","article-title":"Infectious diseases in patients with IRAK-4, MyD88, NEMO, or I\u03baB\u03b1 deficiency","volume":"24","author":"Picard","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jinf.2017.03.005_bib22","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1002\/eji.201242683","article-title":"Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans","volume":"42","author":"Von Bernuth","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jinf.2017.03.005_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/QCO.0b013e3283463e45","article-title":"Factors affecting the development of systemic inflammatory response syndrome in pneumococcal infections","volume":"24","author":"Calbo","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/QCO.0b013e3283608419","article-title":"Current concepts in host-microbe interaction leading to pneumococcal pneumonia","volume":"26","author":"Vernatter","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib25","doi-asserted-by":"crossref","first-page":"010215","DOI":"10.1101\/cshperspect.a010215","article-title":"The pneumococcus: epidemiology, microbiology, and pathogenesis","volume":"3","author":"Henriques-Normark","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4236\/aim.2014.410069","article-title":"Insights into pneumococcal pathogenesis and antibiotic resistance","volume":"4","author":"Donkor","year":"2014","journal-title":"Adv Microbiol"},{"key":"10.1016\/j.jinf.2017.03.005_bib27","series-title":"Community-acquired pneumonia","first-page":"42","article-title":"The pathophysiology of pneumococcal pneumonia","volume":"vol. 63","author":"Wootton","year":"2014"},{"key":"10.1016\/j.jinf.2017.03.005_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3346\/jkms.2013.28.1.4","article-title":"Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance","volume":"28","author":"Song","year":"2013","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jinf.2017.03.005_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/fmb.11.146","article-title":"What is different about serotype 1 pneumococci?","volume":"7","author":"Ritchie","year":"2012","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jinf.2017.03.005_bib30","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00134-006-0182-x","article-title":"Optimal therapy for severe pneumococcal community-acquired pneumonia","volume":"32","author":"Luj\u00e1n","year":"2006","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib31","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.vaccine.2014.02.096","article-title":"Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults","volume":"32","author":"Grabenstein","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2017.03.005_bib32","doi-asserted-by":"crossref","first-page":"e1000081","DOI":"10.1371\/journal.pmed.1000081","article-title":"Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study","volume":"6","author":"Harboe","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib33","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1086\/600045","article-title":"Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome","volume":"49","author":"Jansen","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib34","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/655828","article-title":"Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis","volume":"51","author":"Weinberger","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/thx.2009.123612","article-title":"Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes","volume":"65","author":"Garcia-Vidal","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jinf.2017.03.005_bib36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/1471-2334-13-492","article-title":"High incidence of septic shock caused by Streptococcus pneumoniae serotype 3 \u2013 a retrospective epidemiological study","volume":"13","author":"Ahl","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib37","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1183\/09031936.00050413","article-title":"Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes","volume":"43","author":"Burgos","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2017.03.005_bib38","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1378\/chest.83.4.598","article-title":"Adult respiratory distress syndrome as a cause of death in pneumococcal pneumonia. Report of ten cases","volume":"83","author":"Fruchtman","year":"1983","journal-title":"Chest"},{"key":"10.1016\/j.jinf.2017.03.005_bib39","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1097\/01.CCM.0000220496.48295.A9","article-title":"Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia","volume":"34","author":"Witzenrath","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib40","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1128\/iai.61.4.1352-1358.1993","article-title":"Toxicity of pneumolysin to pulmonary alveolar epithelial cells","volume":"61","author":"Rubins","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.jinf.2017.03.005_bib41","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1097\/01.CCM.0000269212.84709.23","article-title":"Role of platelet-activating factor in pneumolysin-induced acute lung injury","volume":"35","author":"Witzenrath","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1086\/518849","article-title":"The association between pneumococcal pneumonia and acute cardiac events","volume":"45","author":"Musher","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib43","doi-asserted-by":"crossref","first-page":"e1004383","DOI":"10.1371\/journal.ppat.1004383","article-title":"Steptococcus pnemoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function","volume":"10","author":"Brown","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jinf.2017.03.005_bib44","doi-asserted-by":"crossref","first-page":"e1004836","DOI":"10.1371\/journal.ppat.1004836","article-title":"Circulating pneumolysin is a potent inducer of cardiac injury during pneumococcal infection","volume":"11","author":"Alhamdi","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jinf.2017.03.005_bib45","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1164\/rccm.201411-1951PP","article-title":"Cardiotoxicity during invasive pneumococcal disease","volume":"191","author":"Brown","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib46","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib47","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","article-title":"Guidelines for the management of adult lower respiratory tract infections \u2013 full version","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2017.03.005_bib48","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/thoraxjnl-2015-206881","article-title":"British Thoracic Society community-acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together","volume":"70","author":"Lim","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.jinf.2017.03.005_bib49","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1164\/rccm.200311-1578OC","article-title":"Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia","volume":"170","author":"Baddour","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib50","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1128\/AAC.00006-07","article-title":"Comparison of \u03b2-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.03.005_bib51","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","article-title":"Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"42","author":"Sligl","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1378\/chest.13-1531","article-title":"Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000\u20132013)","volume":"146","author":"Gattarello","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.jinf.2017.03.005_bib53","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11908-015-0501-x","article-title":"What is new in antibiotic therapy in community-acquired pneumonia? An evidence-based approach focusing on combined therapy","volume":"17","author":"Gattarello","year":"2015","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.jinf.2017.03.005_bib54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/QCO.0b013e3283232a30","article-title":"Therapy for pneumococcal bacteremia: monotherapy or combination therapy?","volume":"22","author":"Feldman","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib55","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MD.0b013e318178923a","article-title":"Treatment and outcomes for patients with bacteremic pneumococcal pneumonia","volume":"87","author":"Berjohn","year":"2008","journal-title":"Medicine"},{"key":"10.1016\/j.jinf.2017.03.005_bib56","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/cc11471","article-title":"Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study","volume":"16","author":"Mongardon","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.jinf.2017.03.005_bib57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2017.03.005_bib58","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-0032-1315643","article-title":"Adjunctive therapy in community-acquired pneumonia","volume":"33","author":"Wunderink","year":"2012","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib59","series-title":"Community-acquired pneumonia","first-page":"219","article-title":"Non-antibiotic therapies for CAP","volume":"vol. 63","author":"Faverio","year":"2014"},{"key":"10.1016\/j.jinf.2017.03.005_bib60","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/toxins5071244","article-title":"Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs","volume":"5","author":"Lucas","year":"2013","journal-title":"Toxins"},{"key":"10.1016\/j.jinf.2017.03.005_bib61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-94-017-8881-6_8","article-title":"The biology of pneumolysin","volume":"80","author":"Mitchell","year":"2014","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.jinf.2017.03.005_bib62","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/CMR.00024-15","article-title":"Pneumococcal capsules and their types: past, present, and future","volume":"28","author":"Geno","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jinf.2017.03.005_bib63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1128\/JCM.44.1.151-159.2006","article-title":"Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin","volume":"44","author":"Kirkham","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jinf.2017.03.005_bib64","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/520091","article-title":"Presence of nonhemolytic pneumolysin in serotypes of Streptococcus pneumoniae associated with disease outbreaks","volume":"196","author":"Jefferies","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib65","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1128\/JB.01489-08","article-title":"Pneumolysin localizes to the cell wall of Streptococcus pneumonia","volume":"191","author":"Price","year":"2009","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jinf.2017.03.005_bib66","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1073\/pnas.0911581107","article-title":"Only two amino acids are essential for cytolytic toxin recognition of cholesterol at the membrane surface","volume":"107","author":"Farrand","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jinf.2017.03.005_bib67","doi-asserted-by":"crossref","first-page":"10210","DOI":"10.1074\/jbc.M115.691899","article-title":"Red blood cell susceptibility to pneumolysin: correlation with membrane biochemical and physical properties","volume":"291","author":"Bokori-Brown","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jinf.2017.03.005_bib68","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00249-015-1106-x","article-title":"Measuring kinetic drivers of pneumolysin pore structure","volume":"45","author":"Gilbert","year":"2016","journal-title":"Eur Biophys J"},{"key":"10.1016\/j.jinf.2017.03.005_bib69","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.bbamcr.2014.09.005","article-title":"Ca2+-dependent repair of pneumolysin pores: a new paradigm for host cellular defense against bacterial pore-forming toxins","volume":"1853","author":"Wolfmeier","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jinf.2017.03.005_bib70","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.bbagen.2016.07.022","article-title":"Active release of pneumolysin prepores and pores by mammalian cells undergoing a Streptococcus pneumoniae attack","volume":"1860","author":"Wolfmeier","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jinf.2017.03.005_bib71","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.4049\/jimmunol.136.12.4617","article-title":"Oxidative inactivation of pneumolysin by the myeloperoxidase system and stimulated human neutrophils","volume":"136","author":"Clark","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.jinf.2017.03.005_bib72","doi-asserted-by":"crossref","first-page":"e82583","DOI":"10.1371\/journal.pone.0082583","article-title":"Human L-ficolin, a recognition molecule of the lectin activation pathway of complement, activates complement by binding to pneumolysin, the major toxin of Streptococcus pneumoniae","volume":"8","author":"Ali","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jinf.2017.03.005_bib73","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1055\/s-0036-1592074","article-title":"The role of Streptococcus pneumoniae in community-acquired pneumonia","volume":"37","author":"Feldman","year":"2016","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib74","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.chom.2016.12.005","article-title":"Host-to-host transmission of Streptococcus pneumoniae is driven by its inflammatory toxin, pneumolysin","volume":"21","author":"Zafar","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jinf.2017.03.005_bib75","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1128\/IAI.01475-06","article-title":"Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance","volume":"75","author":"Nelson","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.jinf.2017.03.005_bib76","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0882-4010(90)90016-J","article-title":"The effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium in\u00a0vitro","volume":"9","author":"Feldman","year":"1990","journal-title":"Microb Pathog"},{"key":"10.1016\/j.jinf.2017.03.005_bib77","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12223-016-0445-z","article-title":"Pneumolysin plays a key role at the initial step of establishing pneumococcal nasal colonization","volume":"61","author":"Hotomi","year":"2016","journal-title":"Folia Microbiol"},{"key":"10.1016\/j.jinf.2017.03.005_bib78","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/21645515.2016.1234553","article-title":"Preclinical evaluation of a chemically detoxified pneumolysin as pneumococcal vaccine antigen","volume":"13","author":"Hermand","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jinf.2017.03.005_bib79","first-page":"1899","article-title":"Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice","volume":"119","author":"Zhang","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jinf.2017.03.005_bib80","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1242\/jcs.035600","article-title":"Integrin-linked kinase is required for vitronectin-mediated internalization of Streptococcus pneumoniae by host cells","volume":"122","author":"Bergmann","year":"2009","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jinf.2017.03.005_bib81","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2431-11-94","article-title":"Multi-species bacterial biofilm and intracellular infection in otitis media","volume":"11","author":"Thornton","year":"2011","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.jinf.2017.03.005_bib82","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1128\/IAI.00488-12","article-title":"Pneumococcal interactions with epithelial cells are crucial for optimal biofilm formation and colonization in\u00a0vitro and in\u00a0vivo","volume":"80","author":"Marks","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.jinf.2017.03.005_bib83","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1128\/CMR.00058-05","article-title":"Insights into the interaction between influenza virus and pneumococcus","volume":"19","author":"McCullers","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jinf.2017.03.005_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1465-9921-14-41","article-title":"M2 macrophage polarisation is associated with alveolar formation during postnatal lung development","volume":"14","author":"Jones","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.jinf.2017.03.005_bib85","doi-asserted-by":"crossref","DOI":"10.1080\/08923973.2016.1248845","article-title":"Regulatory effects of miR-155 and miR-146a on repolarization and inflammatory cytokine secretion in human alveolar macrophages in\u00a0vitro","author":"Yang","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.jinf.2017.03.005_bib86","doi-asserted-by":"crossref","first-page":"e1005337","DOI":"10.1371\/journal.ppat.1005337","article-title":"Pore-forming toxins induce macrophage necroptosis during acute bacterial pneumonia","volume":"11","author":"Gonz\u00e1lez-Juarbe","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jinf.2017.03.005_bib87","doi-asserted-by":"crossref","first-page":"e1004820","DOI":"10.1371\/journal.ppat.1004820","article-title":"Toxin-induced necroptosis is a major mechanism of Staphylococcus aureus lung damage","volume":"11","author":"Kitur","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jinf.2017.03.005_bib88","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1128\/IAI.00007-16","article-title":"Infiltrated macrophages die of pneumolysin-mediated necroptosis following pneumococcal myocardial invasion","volume":"84","author":"Gilley","year":"2016","journal-title":"Infect Immun"},{"key":"10.1016\/j.jinf.2017.03.005_bib89","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/cei.12170","article-title":"Alveolar macrophages in pulmonary host defence the unrecognized role of apoptosis as a mechanism of intracellular bacterial killing","volume":"174","author":"Aberdein","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jinf.2017.03.005_bib90","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01710-14","article-title":"Pneumolysin activates macrophage lysosomal membrane permeabilization and executes apoptosis by distinct mechanisms without membrane pore formation","volume":"5","author":"Bewley","year":"2014","journal-title":"MBio"},{"key":"10.1016\/j.jinf.2017.03.005_bib91","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/cr.2013.171","article-title":"Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death","volume":"24","author":"Chen","year":"2014","journal-title":"Cell Res"},{"key":"10.1016\/j.jinf.2017.03.005_bib92","doi-asserted-by":"crossref","first-page":"e02110","DOI":"10.1128\/mBio.02110-14","article-title":"Degradation products of the extracellular pathogen Streptotoccus pneumoniae access the cytosol via its pore-forming toxin","volume":"6","author":"Lemon","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.jinf.2017.03.005_bib93","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4049\/jimmunol.1401624","article-title":"Neutrophil IL-1\u03b2 processing induced by pneumolysin is mediated by the NLRP3\/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux","volume":"194","author":"Karmakar","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jinf.2017.03.005_bib94","doi-asserted-by":"crossref","DOI":"10.1038\/mi.2016.113","article-title":"Neutrophilic NLRP3 inflammasome-dependent IL-1\u03b2 secretion regulates the \u03b3\u03b4T17 cell response in respiratory bacterial infections","author":"Hassane","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jinf.2017.03.005_bib95","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1465-9921-8-3","article-title":"The role of pneumolysin in mediating lung damage in a lethal pneumococcal pneumonia murine model","volume":"8","author":"Garc\u00eda-Su\u00e1rez Mdel","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.jinf.2017.03.005_bib96","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1600-0463.2011.02813.x","article-title":"Characterization of recombinant Streptococcus mitis-derived human platelet aggregation factor","volume":"120","author":"Ohkuni","year":"2012","journal-title":"APMIS"},{"key":"10.1016\/j.jinf.2017.03.005_bib97","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00408-016-9900-5","article-title":"Pneumolysin mediates platelet activation in\u00a0vitro","volume":"194","author":"Nel","year":"2016","journal-title":"Lung"},{"key":"10.1016\/j.jinf.2017.03.005_bib98","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jinf.2017.02.010","article-title":"Pneumolysin mediates heterotypic aggregation of neutrophils and platelets in\u00a0vitro","volume":"74","author":"Nel","year":"2017","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2017.03.005_bib99","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib100","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1016\/j.vaccine.2015.07.080","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska","volume":"33","author":"Bruce","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2017.03.005_bib101","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12879-016-1693-x","article-title":"Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children","volume":"16","author":"Nair","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib102","first-page":"477","article-title":"Community-acquired pneumonia: still a major burden of disease","volume":"22","author":"Feldman","year":"2016","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.jinf.2017.03.005_bib103","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1128\/IAI.72.8.4534-4540.2004","article-title":"Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin","volume":"72","author":"Garc\u00eda-Su\u00e1rez Mdel","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.jinf.2017.03.005_bib104","first-page":"189","article-title":"Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease","volume":"53","author":"Cockeran","year":"2005","journal-title":"Arch Immunol Ther Exp"},{"key":"10.1016\/j.jinf.2017.03.005_bib105","doi-asserted-by":"crossref","first-page":"17668","DOI":"10.1038\/srep17668","article-title":"\u03b2-Sitosterol interacts with pneumolysin to prevent Streptococcus pneumoniae infection","volume":"5","author":"Li","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jinf.2017.03.005_bib106","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nbt.3037","article-title":"Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice","volume":"33","author":"Henry","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jinf.2017.03.005_bib107","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1124\/mol.115.100610","article-title":"Verbascoside alleviates pneumococcal pneumonia by reducing pneumolysin oligomers","volume":"89","author":"Zhao","year":"2016","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jinf.2017.03.005_bib108","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.fitote.2016.09.017","article-title":"Apigenin protects mice from pneumococcal pneumonia by inhibiting the cytolytic activity of pneumolysin","volume":"115","author":"Song","year":"2016","journal-title":"Fitoterapia"},{"key":"10.1016\/j.jinf.2017.03.005_bib109","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1248\/bpb.b16-00598","article-title":"Anticytotoxin effects of amentoflavone to pneumolysin","volume":"40","author":"Zhao","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jinf.2017.03.005_bib110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/1471-2334-14-335","article-title":"Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis","volume":"14","author":"Spoorenberg","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib111","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib112","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","article-title":"Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia","volume":"36","author":"Martin-Loeches","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib113","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MCP.0000000000000257","article-title":"Improving outcomes in community-acquired pneumonia","volume":"22","author":"Bender","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib114","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.resinv.2015.05.003","article-title":"Update on the combination effect of macrolide antibiotics in community-acquired pneumonia","volume":"53","author":"Emmet O'Brien","year":"2015","journal-title":"Respir Investig"},{"key":"10.1016\/j.jinf.2017.03.005_bib115","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/resp.12835","article-title":"Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis","volume":"21","author":"Horita","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.jinf.2017.03.005_bib116","doi-asserted-by":"crossref","first-page":"e002898","DOI":"10.1136\/bmjopen-2013-002898","article-title":"Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study","volume":"3","author":"Shorr","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jinf.2017.03.005_bib117","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3390\/ph3051694","article-title":"Beneficial and harmful interactions of antibiotics with microbial pathogens and the host innate immune system","volume":"3","author":"Anderson","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jinf.2017.03.005_bib118","doi-asserted-by":"crossref","first-page":"584262","DOI":"10.1155\/2012\/584262","article-title":"Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics","volume":"2012","author":"Steel","year":"2012","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jinf.2017.03.005_bib119","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/jac\/46.5.717","article-title":"Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in\u00a0vitro","volume":"46","author":"Lagrou","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2017.03.005_bib120","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1128\/AAC.47.8.2649-2654.2003","article-title":"Reduced release of pneumolysin by Streptococcus pneumoniae in\u00a0vitro and in\u00a0vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone","volume":"47","author":"Spreer","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.03.005_bib121","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/jac\/dkl479","article-title":"Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae","volume":"59","author":"Anderson","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2017.03.005_bib122","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/jac\/dkm338","article-title":"Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in\u00a0vitro","volume":"60","author":"Anderson","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2017.03.005_bib123","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000107691","article-title":"Influence of subinhibitory concentrations of protein-synthesis-inhibiting antibiotics on production and release of the pneumococcal virulence factor pneumolysin in\u00a0vitro","volume":"53","author":"Spreer","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jinf.2017.03.005_bib124","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1183\/09031936.06.00116805","article-title":"Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae","volume":"27","author":"Fukuda","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2017.03.005_bib125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2169\/internalmedicine.48.1482","article-title":"Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection","volume":"48","author":"Yanagihara","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib126","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jiac.2013.10.010","article-title":"Contradiction between in\u00a0vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia","volume":"20","author":"Kohno","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jinf.2017.03.005_bib127","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1093\/jac\/dku207","article-title":"Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data","volume":"69","author":"Zhanel","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2017.03.005_bib128","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1128\/AAC.01074-07","article-title":"Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation","volume":"52","author":"Wolter","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.03.005_bib129","first-page":"1","article-title":"Effects of clarithromycin at sub-minimum inhibitory concentrations on early ermB gene expression, metabolic activity and growth of an erm(B)-expressing macrolide-resistant strain of Streptococcus pneumoniae","volume":"2","author":"Cockeran","year":"2012","journal-title":"Open J Respir Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib130","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.idc.2004.04.010","article-title":"Macrolides and ketolides: azithromycin, clarithromycin, telithromycin","volume":"18","author":"Zuckerman","year":"2004","journal-title":"Infect Dis Clin N Am"},{"key":"10.1016\/j.jinf.2017.03.005_bib131","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/AAC.39.4.797","article-title":"Insights into erythromycin action from studies of its activity as inducer of resistance","volume":"39","author":"Weisblum","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.03.005_bib132","doi-asserted-by":"crossref","DOI":"10.1378\/chest.125.2_suppl.62S","article-title":"Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa","volume":"125","author":"Wozniak","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jinf.2017.03.005_bib133","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1164\/rccm.201502-0212OC","article-title":"The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia","volume":"191","author":"Cilloniz","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib134","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1164\/rccm.201504-0701ED","article-title":"Macrolide-resistant pneumococcus in community-acquired pneumonia. Is there still a role for macrolide therapy?","volume":"191","author":"Niederman","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib135","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1128\/AAC.47.3.1151-1153.2003","article-title":"Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in\u00a0vitro","volume":"47","author":"Lin","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.03.005_bib136","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1128\/AAC.01024-16","article-title":"Efficacy of \u03b2-lactam-plus-macrolide combination therapy in a mouse model of lethal pneumococcal pneumonia","volume":"60","author":"Yoshioka","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.03.005_bib137","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1586\/14787210.2016.1138857","article-title":"The role of solithromycin in the management of bacterial community-acquired pneumonia","volume":"14","author":"Van Bambeke","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jinf.2017.03.005_bib138","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1128\/AAC.04568-14","article-title":"Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012","volume":"59","author":"Farrell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.03.005_bib139","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17476348.2017.1249852","article-title":"Solithromycin for the treatment of community-acquired bacterial pneumonia","volume":"11","author":"Viasus","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib140","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.phrs.2016.07.033","article-title":"Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3","volume":"111","author":"Yamamoto","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jinf.2017.03.005_bib141","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1124\/jpet.116.233932","article-title":"Premedication with clarithromycin is effective against secondary bacterial pneumonia during influenza virus infection in a pulmonary emphysema mouse model","volume":"358","author":"Harada","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jinf.2017.03.005_bib142","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nm1765","article-title":"Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection","volume":"14","author":"Sun","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib143","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type I interferon: friend or foe?","volume":"207","author":"Trinchieri","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib144","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12931-015-0165-y","article-title":"Lung inflammatory pattern and antibiotic treatment in pneumonia","volume":"16","author":"Lorenzo","year":"2015","journal-title":"Respir Res"},{"key":"10.1016\/j.jinf.2017.03.005_bib145","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1165\/rcmb.2014-0391OC","article-title":"Statin-conferred enhanced cellular resistance against bacterial pore-forming toxins in airway epithelial cells","volume":"53","author":"Statt","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jinf.2017.03.005_bib146","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1172\/JCI39843","article-title":"Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease","volume":"120","author":"Rosch","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jinf.2017.03.005_bib147","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1378\/chest.15-0484","article-title":"Community-acquired pneumonia. Pathogenesis of acute cardiac events and potential adjunctive therapies","volume":"148","author":"Feldman","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jinf.2017.03.005_bib148","doi-asserted-by":"crossref","first-page":"e006251","DOI":"10.1136\/bmjopen-2014-006251","article-title":"The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Viasus","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.jinf.2017.03.005_bib149","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/cid\/ciw174","article-title":"Statin use and hospital length of stay among adults hospitalized with community-acquired pneumonia","volume":"62","author":"Havers","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib150","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/thoraxjnl-2016-208505","article-title":"Recovery from pneumonia requires efferocytosis which is impaired in smokers and those with low body mass index and enhanced by statins","volume":"71","author":"Wootton","year":"2016","journal-title":"Thorax"},{"issue":"Suppl. 3","key":"10.1016\/j.jinf.2017.03.005_bib151","doi-asserted-by":"crossref","first-page":"A11","DOI":"10.1136\/thoraxjnl-2016-209333.22","article-title":"Simvastatin improves neutrophil migration in elderly patients with septic pneumonia and reduces 6-month mortality and re-admissions: results of the SNOOPI Trial","volume":"71","author":"Patel","year":"2016","journal-title":"Thorax"},{"issue":"Suppl. 3","key":"10.1016\/j.jinf.2017.03.005_bib152","doi-asserted-by":"crossref","first-page":"A231","DOI":"10.1136\/thoraxjnl-2016-209333.408","article-title":"Concurrent statin and macrolide use during pneumonia treatment improves survival to hospital discharge and beyond","volume":"71","author":"Grudzinska","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jinf.2017.03.005_bib153","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00281-013-0366-8","article-title":"Pharmacological approaches to regulate neutrophil activity","volume":"335","author":"Tintinger","year":"2013","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jinf.2017.03.005_bib154","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1476-5381.2010.01199.x","article-title":"Glucocorticosteroids: current and future directions","volume":"163","author":"Barnes","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jinf.2017.03.005_bib155","first-page":"E635","article-title":"Glucocorticoid-induced tethered transrepression requires SUMOylation of GR and formation of a SUMO-SMRT\/NCoR1-HDAC3 repressing complex","volume":"113","author":"Hua","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jinf.2017.03.005_bib156","first-page":"197","article-title":"The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin","volume":"98","author":"Wagner","year":"1956","journal-title":"Bull Johns Hopkins Hosp"},{"key":"10.1016\/j.jinf.2017.03.005_bib157","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/jcp.56.11.879","article-title":"Corticosteroids as adjunctive treatment in Austrian's syndrome (pneumococcal endocarditis, meningitis, and pneumonia): report of two cases and review of the literature","volume":"56","author":"du Cheyron","year":"2003","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jinf.2017.03.005_bib158","first-page":"186302","article-title":"Systemic steroid treatment for severe expanding pneumococcal pneumonia","volume":"2015","author":"Lavi","year":"2015","journal-title":"Case Rep Pediatr"},{"key":"10.1016\/j.jinf.2017.03.005_bib159","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ajpath.2013.05.016","article-title":"Marked improvement of severe lung immunopathology by influenza-associated pneumococcal superinfection requires the control of both bacterial replication and host immune responses","volume":"183","author":"Damjanovic","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jinf.2017.03.005_bib160","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/infdis\/jit653","article-title":"Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice","volume":"209","author":"Ghoneim","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib161","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/M15-0715","article-title":"Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis","volume":"163","author":"Siemieniuk","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib162","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1183\/09031936.00081514","article-title":"Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients","volume":"45","author":"Tagami","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2017.03.005_bib163","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.21037\/jtd.2016.02.43","article-title":"Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials","volume":"8","author":"Feldman","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib164","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1183\/13993003.00474-2016","article-title":"Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia","volume":"48","author":"Wirz","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jinf.2017.03.005_bib165","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(14)62447-8","article-title":"Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"385","author":"Blum","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2017.03.005_bib166","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.200905-0808OC","article-title":"Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial","volume":"181","author":"Snijders","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib167","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fcimb.2016.00128","article-title":"Effects of suilysin on Streptococcus suis-induced platelet aggregation","volume":"6","author":"Zhang","year":"2016","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jinf.2017.03.005_bib168","doi-asserted-by":"crossref","first-page":"36787","DOI":"10.1038\/srep36787","article-title":"Suilysin-induced platelet-neutrophil complexes formation is triggered by pore formation-dependent calcium influx","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jinf.2017.03.005_bib169","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1160\/TH14-02-0126","article-title":"The role of platelets in sepsis","volume":"112","author":"De Stoppelaar","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jinf.2017.03.005_bib170","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2015-11-680744","article-title":"Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients","volume":"127","author":"Claushuis","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jinf.2017.03.005_bib171","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2014.07.985","article-title":"Platelet activation is associated with myocardial infarction in patients with pneumonia","volume":"64","author":"Cangemi","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jinf.2017.03.005_bib172","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jinf.2016.05.013","article-title":"Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia","volume":"73","author":"Cangemi","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2017.03.005_bib173","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/09537100802503368","article-title":"Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms","volume":"20","author":"Winning","year":"2009","journal-title":"Platelets"},{"key":"10.1016\/j.jinf.2017.03.005_bib174","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1378\/chest.10-0891","article-title":"Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study","volume":"139","author":"Erlich","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jinf.2017.03.005_bib175","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1097\/CCM.0b013e3182120992","article-title":"Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury\/acute respiratory distress syndrome","volume":"39","author":"O'Neal","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib176","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/CCM.0b013e31826ab38b","article-title":"Anti-platelet therapy is associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients","volume":"41","author":"Harr","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib177","doi-asserted-by":"crossref","first-page":"e001595","DOI":"10.1161\/JAHA.114.001595","article-title":"Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin","volume":"4","author":"Falcone","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jinf.2017.03.005_bib178","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/SHK.0000000000000745","article-title":"Prevention or treatment of ARDS with aspirin: a\u00a0review of preclinical models and meta-analysis of\u00a0clinical\u00a0studies","volume":"47","author":"Panka","year":"2016","journal-title":"Shock"},{"key":"10.1016\/j.jinf.2017.03.005_bib179","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1097\/CCM.0b013e318225757f","article-title":"Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients","volume":"39","author":"Kor","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jinf.2017.03.005_bib180","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2016.6330","article-title":"Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS-A randomized clinical trial","volume":"315","author":"Kor","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2017.03.005_bib181","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1378\/chest.09-3102","article-title":"Nonsteroidal anti-inflammatory drugs may affect the presentation and course of community-acquired pneumonia","volume":"139","author":"Voiriot","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.jinf.2017.03.005_bib182","first-page":"200544","article-title":"Lung abscess complicating pneumococcal pneumonia: a causal role of non-steroidal anti-inflammatory drugs?","author":"Gibelin","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jinf.2017.03.005_bib183","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jcrc.2014.05.021","article-title":"Risks of nonsteroidal anti-inflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: younger and more severely affected patients","volume":"29","author":"Messika","year":"2014","journal-title":"J Crit Care"},{"key":"10.1016\/j.jinf.2017.03.005_bib184","first-page":"857","article-title":"Aspirin impairs antibacterial mechanisms in experimental pneumococcal pneumonia","volume":"130","author":"Esposito","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib185","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1182\/blood-2010-05-284844","article-title":"Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and \u2013resistant bacteria","volume":"116","author":"Stables","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jinf.2017.03.005_bib186","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2334-14-47","article-title":"Aspirin enhances opsonophagocytosis and is associated to a lower risk for Klebsiella pneumoniae invasive syndrome","volume":"14","author":"Lee","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2017.03.005_bib187","doi-asserted-by":"crossref","first-page":"34560","DOI":"10.1038\/srep34560","article-title":"Leukotriene B4 receptor type 2 protects against pneumolysin-dependent acute lung injury","volume":"6","author":"Shigematsu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jinf.2017.03.005_bib188","series-title":"CADTH issues in emerging health technologies","first-page":"148","article-title":"PAR-1 antagonists: an emerging antiplatelet drug class","author":"Pan","year":"2016"},{"key":"10.1016\/j.jinf.2017.03.005_bib189","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.4049\/jimmunol.1500124","article-title":"Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection","volume":"194","author":"Jos\u00e9","year":"2015","journal-title":"J Immunol"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445317300828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445317300828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:24:07Z","timestamp":1759008247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445317300828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":189,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0163445317300828"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2017.03.005","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumolysin as a potential therapeutic target in severe pneumococcal disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2017.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}